CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 8 enrolled
Drug / intervention
Vivaglobinbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00701662
NCT00701662Phase 2Completed
CompareCT.gov

A Multicentre Study of Subcutaneous Immunoglobulin (SCIG) in Patients With Multifocal Motor Neuropathy (MMN)

CSL Behring·interventional·Posted Jun 19, 2008·Updated Aug 1, 2013

In Brief

A Phase 2 clinical trial evaluating Vivaglobin for Multifocal Motor Neuropathy (MMN). Completed, enrolled 8 participants across 3 sites in 3 countries.

Detailed Summary

The objective of this study is to assess efficacy, safety, and convenience of purified human antibodies administered under the skin in the treatment of MMN patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultifocal Motor Neuropathy (MMN)
CountriesItaly, Switzerland, United Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 19, 2008
Enrollment StartNov 1, 2007
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 18.0 years ago

Interventions

Vivaglobinbiological